A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study ...

However, it seems to be making a resurgence, with three new forms for at-home use approved for the acute treatment of migraine — one in 2021 and another two in 2025. Dihydroergotamine Mesylate ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Scientists haven’t found a cure for migraines, but they’re better at treating the symptoms. In fact, they’ve made more advances in migraine treatment in the last 2 years than in the previous ...

Pulsating headaches plus light sensitivity or vomiting: Migraine sufferers know well that the symptoms can go way beyond a headache. They also vary from one person to the next. You may be ...

The National Institutes of Health spent only $40 million on migraine research in 2021; by comparison, ... If you can’t get relief, discuss new treatments with your doctor.

The obesity drug liraglutide cut migraine days in half in a small trial, though more research is needed to exclude the placebo effect, researchers said.

The first was the phase 3, open-label long-term safety ASCEND study in which 446 patients treated more than 9,000 migraine attacks with more than 10,500 doses of STS101 for up to 18 months.

While the BMJ study focused on acute treatment of migraines, new CGRP treatments have also been approved as preventatives. Nurtec pills, for example, were approved in 2021 for use every other day ...

DARIEN, Conn., Aug. 20, 2024 /PRNewswire/ -- CEFALY Technology today launched the all-new CeCe Migraine Management app, which features two-way communication with the CEFALY Connected device.